OneMedPlace Interviews Jeffrey Davis, CEO of Access Pharmaceuticals

Last month, OneMedPlace reported on MuGard, a preventive oral mucositis treatment from Dallas-based Access Pharmaceuticals (ACCP). MuGard has performed extremely well in post-approval studies, and is poised to break into a $5 billion worldwide market.

OneMedPlace recently sat down with Jeffrey Davis, CEO of Access Pharmaceuticals, to discuss the clinical success of MuGard and the latest news surrounding the product’s launch.

The comments are closed.